Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SRRK

Scholar Rock Holding Corp

Dec 26 • 04:00PM ET

45.67

-0.19 -0.41 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE TVRD

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-3.25	Insider Own	20.08%	Shs Outstand	99.17M	Perf Week	6.38%
Market Cap	4.66B	Forward P/E	-	EPS next Y	-3.09	Insider Trans	1.73%	Shs Float	81.52M	Perf Month	10.13%
Enterprise Value	4.40B	PEG	-	EPS next Q	-0.89	Inst Own	100.93%	Short Float	20.42%	Perf Quarter	17.86%
Income	-353.43M	P/S	-	EPS this Y	-39.14%	Inst Trans	8.16%	Short Ratio	7.19	Perf Half Y	27.53%
Sales	0.00M	P/B	18.49	EPS next Y	10.09%	ROA	-119.63%	Short Interest	16.65M	Perf YTD	5.67%
Book/sh	2.47	P/C	12.60	EPS next 5Y	8.65%	ROE	-218.04%	52W High	48.28 -5.41%	Perf Year	3.89%
Cash/sh	3.62	P/FCF	-	EPS past 3/5Y	11.76% -5.90%	ROIC	-101.05%	52W Low	22.71 101.10%	Perf 3Y	485.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.05% 4.51%	Perf 5Y	-4.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-31.71%	Oper. Margin	-	ATR (14)	1.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.33	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	6.30	EPS Q/Q	-35.28%	SMA20	2.34%	Beta	0.64	Target Price	47.92
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	22.56%	Rel Volume	0.22	Prev Close	45.86
Employees	196	LT Debt/Eq	0.43	Earnings	Nov 14 BMO	SMA200	32.61%	Avg Volume	2.32M	Price	45.67
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.85% -100.00%	Trades		Volume	510,782	Change	-0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Outperform	$42
Oct-09-25	Initiated	BofA Securities	Buy	$53
Sep-17-25	Initiated	Barclays	Overweight	$45
Sep-15-25	Initiated	Leerink Partners	Outperform	$51
Aug-21-25	Resumed	Jefferies	Buy	$50
Jul-30-25	Resumed	Raymond James	Strong Buy	$53
Jul-17-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59

Show Previous Ratings

Dec-13-25 10:57AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-25 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire) +9.14%
Nov-16-25 11:16AM	Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses (Insider Monkey)
Nov-15-25 07:07AM	Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress (Insider Monkey)
Nov-14-25 02:02PM	Scholar Rock Holding Corp (SRRK) Q3 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com) +24.41%
07:00AM	Loading…
07:00AM	Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Nov-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:15AM	3 Beaten-Down Stocks With Rebound Potential This Earnings Season (MarketBeat)
Nov-04-25 08:00AM	Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-23-25 08:00AM	Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 (Business Wire)
Oct-17-25 06:15PM	Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Oct-13-25 05:22PM	Why Scholar Rock Stock Got Socked on Monday (Motley Fool) -13.14% -6.93%
Oct-09-25 05:07PM	Why Scholar Rock Stock Raced 6% Higher Today (Motley Fool) +5.94%
01:10PM	Loading…
Oct-08-25 01:10PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-23-25 04:06PM	Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback (Investor's Business Daily)
10:04AM	Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
07:00AM	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility (Business Wire)
06:19AM	Scholar Rock SMA drug rejected by FDA over manufacturing concerns (BioPharma Dive)
Sep-15-25 04:54PM	Why Scholar Rock Stock Bounced Higher on Monday (Motley Fool) +6.32%
Sep-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 03:31AM	Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger? (Insider Monkey)
Aug-21-25 12:18PM	Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD (Insider Monkey)
Aug-15-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-14-25 08:00AM	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment (Business Wire)
Aug-11-25 08:21PM	Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss (Insider Monkey)
Aug-06-25 05:10PM	Why Scholar Rock Stock Wilted on Wednesday (Motley Fool) -6.40% -9.30%
07:00AM	Loading…
07:00AM	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
Jul-21-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 (Business Wire)
Jul-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-25 08:00AM	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial (Business Wire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters) -6.28%
Jun-19-25 02:01PM	Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial (Insider Monkey)
Jun-18-25 01:41PM	Why Scholar Rock Shares Are Soaring Today (Motley Fool) +16.60%
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
07:42AM	Scholar Rock drug preserves muscle in obesity trial (BioPharma Dive)
07:00AM	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss (Business Wire)
Jun-13-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%
Apr-21-25 04:37PM	Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ... (GuruFocus.com) +6.14%
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 07:30AM	FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy (Business Wire)
Mar-17-25 08:31AM	Scholar Rock SMA drug shows muscle function benefit (Clinical Trials Arena)
Mar-16-25 07:00PM	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Mar-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 11:16PM	Q4 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents) +7.95%
07:00AM	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress (Business Wire)
Feb-26-25 07:24AM	Earnings To Watch: Scholar Rock Holding Corp (SRRK) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 04:15PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 01:10PM	Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now? (Insider Monkey)
Feb-21-25 08:00AM	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025 (Business Wire)
Jan-29-25 08:05AM	Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
08:00AM	Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition (Business Wire)
Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Peng Katie	Director	Dec 16 '25	Sale	44.09	1,006	44,352	32,908	Dec 18 04:30 PM
AKKARAJU SRINIVAS	Director	Oct 07 '25	Buy	39.92	29,599	1,181,634	530,038	Dec 16 09:07 PM
Katie Peng	Director	Dec 16 '25	Proposed Sale	45.24	1,006	45,511		Dec 16 06:02 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Option Exercise	21.21	136,462	2,894,077	245,426	Dec 05 04:53 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Sale	45.21	136,462	6,169,788	108,964	Dec 05 04:53 PM
Mohammed Qatanani	Officer	Dec 04 '25	Proposed Sale	43.01	149,574	6,433,178		Dec 04 04:19 PM
AKKARAJU SRINIVAS	Director	Oct 03 '25	Buy	37.27	387,414	14,438,544	387,414	Oct 07 08:59 PM
AKKARAJU SRINIVAS	Director	Oct 06 '25	Buy	38.65	113,025	4,368,808	500,439	Oct 07 08:59 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 22 '25	Sale	30.67	3,353	102,846	108,964	Sep 24 04:30 PM
Mohammed Qatanani	Officer	Sep 22 '25	Proposed Sale	30.67	3,353	102,846		Sep 22 04:33 PM
Peng Katie	Director	Sep 16 '25	Sale	32.53	1,006	32,726	33,914	Sep 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '25	Sale	33.52	3,178	106,527	112,317	Sep 17 04:30 PM
Katie Peng	Director	Sep 16 '25	Proposed Sale	32.53	1,006	32,726		Sep 16 04:32 PM
Parlavecchio Caryn	CHRO	Aug 18 '25	Sale	31.17	2,178	67,880	155,464	Aug 19 04:30 PM
FLIER JEFFREY S.	Director	Jul 16 '25	Sale	40.02	11,136	445,688	0	Jul 18 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jul 08 '25	Sale	34.44	24,066	828,898	115,495	Jul 10 09:46 PM
Mohammed Qatanani	Officer	Jul 08 '25	Proposed Sale	35.48	24,066	853,862		Jul 08 04:12 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Option Exercise	21.62	20,316	439,232	44,386	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	32.24	20,316	654,904	24,070	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	33.21	11,136	369,818	11,136	Jun 25 04:30 PM
Peng Katie	Director	Jun 16 '25	Sale	31.97	3,031	96,888	34,920	Jun 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 16 '25	Sale	32.00	3,668	117,381	139,561	Jun 17 04:30 PM
Parlavecchio Caryn	CHRO	Jun 16 '25	Sale	32.00	6,186	197,961	157,642	Jun 17 04:30 PM
Ho Junlin	GENERAL COUNSEL	Jun 16 '25	Sale	32.00	7,442	238,154	222,569	Jun 17 04:30 PM
Edward Myles	Former Officer	Jun 05 '25	Proposed Sale	32.50	19,599	636,967		Jun 05 04:57 PM
FLIER JEFFREY S.	Director	May 29 '25	Sale	29.73	6,075	180,584	24,070	May 30 04:32 PM
Burow Kristina	Director	May 29 '25	Sale	29.72	5,400	160,511	21,071	May 30 04:31 PM
Gilman Michael	Director	May 29 '25	Sale	29.72	3,375	100,304	55,216	May 30 04:31 PM
Brudnick Richard	Director	May 29 '25	Sale	29.72	6,075	180,531	15,057	May 30 04:31 PM
Reed Joshua	Director	May 29 '25	Sale	29.72	5,400	160,463	15,732	May 30 04:30 PM
Vaishnaw Akshay	President of R&D	May 29 '25	Sale	29.72	6,750	200,612	616,205	May 30 04:30 PM
Akshay Vaishnaw	Director	May 29 '25	Proposed Sale	29.66	6,750	200,205		May 29 04:51 PM
Joshua Reed	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:49 PM
Michael Gilman	Director	May 29 '25	Proposed Sale	29.66	3,375	100,103		May 29 04:46 PM
Jeffrey S. Flier	Director	May 29 '25	Proposed Sale	29.66	48,663	1,443,345		May 29 04:43 PM
Kristina Burow	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:39 PM
Richard Brudnick	Director	May 29 '25	Proposed Sale	29.66	6,075	180,185		May 29 04:35 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Option Exercise	10.00	5,000	50,000	76,250	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Sale	32.83	5,000	164,131	71,750	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Option Exercise	10.00	5,000	50,000	78,250	Mar 25 07:39 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Sale	33.08	6,500	215,014	71,750	Mar 25 07:39 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Option Exercise	17.33	13,564	235,085	96,173	Mar 25 07:37 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Sale	33.12	13,564	449,237	82,609	Mar 25 07:37 PM
Tracey Sacco	Affiliate	Mar 24 '25	Proposed Sale	33.00	41,500	1,369,500		Mar 24 07:20 PM
Peng Katie	Director	Mar 17 '25	Sale	34.42	1,006	34,627	30,319	Mar 19 05:00 PM
Katie Peng	Director	Mar 17 '25	Proposed Sale	34.60	4,037	139,680		Mar 17 06:50 PM
Myles Edward H	COO & CFO	Mar 10 '25	Option Exercise	13.60	112,897	1,535,083	253,637	Mar 12 07:06 PM
Myles Edward H	COO & CFO	Mar 10 '25	Sale	35.62	142,292	5,068,974	111,345	Mar 12 07:06 PM
Edward Myles	Officer	Mar 10 '25	Proposed Sale	35.00	161,890	5,666,150		Mar 10 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Option Exercise	10.19	48,308	492,186	179,594	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Sale	37.40	68,510	2,562,479	111,084	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	36.83	4,135	152,288	131,286	Feb 20 07:55 PM
Parlavecchio Caryn	CHRO	Feb 18 '25	Sale	36.83	5,296	195,046	140,258	Feb 20 06:30 PM
Myles Edward H	COO & CFO	Feb 18 '25	Sale	36.83	7,809	287,598	140,740	Feb 20 06:18 PM
Ho Junlin	GENERAL COUNSEL	Feb 18 '25	Sale	36.83	5,742	211,472	189,295	Feb 20 05:53 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	36.83	18,372	676,622	311,991	Feb 20 05:41 PM
Mohammed Qatanani	Officer	Feb 19 '25	Proposed Sale	36.95	68,510	2,531,444		Feb 19 04:15 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Jan 16 '25	Sale	44.20	22,308	985,951	330,363	Jan 21 04:35 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '25	Sale	44.20	5,655	249,935	67,200	Jan 21 04:35 PM
Sacco Tracey	Chief Commercial Officer	Jan 16 '25	Sale	44.20	3,890	171,927	45,395	Jan 21 04:35 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '25	Sale	44.20	7,347	324,717	135,421	Jan 21 04:35 PM
Parlavecchio Caryn	CHRO	Jan 16 '25	Sale	44.20	6,434	284,365	145,554	Jan 21 04:35 PM
Myles Edward H	COO & CFO	Jan 16 '25	Sale	44.20	12,539	554,189	148,549	Jan 21 04:35 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '25	Sale	44.20	9,039	399,498	195,037	Jan 21 04:35 PM

Open in Screener

ALMS

Alumis Inc

Dec 26 • 04:00PM ET

10.97

-0.43 -3.77 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD REGN VRTX BIIB MRNA INCY BMY ABBV PFE

| Held by: VTI IWM IWN VXF IBB SCHA VTWO IWC PRFZ VHT

Index	RUT	P/E	-	EPS (ttm)	-3.85	Insider Own	41.88%	Shs Outstand	97.17M	Perf Week	-0.81%
Market Cap	1.15B	Forward P/E	-	EPS next Y	-3.16	Insider Trans	7.38%	Shs Float	60.67M	Perf Month	49.66%
Enterprise Value	805.28M	PEG	-	EPS next Q	-0.95	Inst Own	47.02%	Short Float	6.39%	Perf Quarter	170.86%
Income	-245.15M	P/S	51.77	EPS this Y	71.87%	Inst Trans	-0.32%	Short Ratio	3.98	Perf Half Y	263.25%
Sales	22.12M	P/B	2.98	EPS next Y	-8.30%	ROA	-54.44%	Short Interest	3.87M	Perf YTD	39.57%
Book/sh	3.69	P/C	3.03	EPS next 5Y	35.43%	ROE	-66.88%	52W High	12.44 -11.82%	Perf Year	31.06%
Cash/sh	3.62	P/FCF	-	EPS past 3/5Y	-58.27% -	ROIC	-58.63%	52W Low	2.76 297.45%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	84.41%	Volatility	4.11% 7.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	36.41	EPS Y/Y TTM	13.80%	Oper. Margin	-1994.85%	ATR (14)	0.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.01	Sales Y/Y TTM	-	Profit Margin	-1108.24%	RSI (14)	65.02	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.01	EPS Q/Q	37.84%	SMA20	5.41%	Beta	-1.91	Target Price	19.86
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	48.83%	Rel Volume	0.72	Prev Close	11.40
Employees	168	LT Debt/Eq	0.09	Earnings	Nov 13 AMC	SMA200	112.60%	Avg Volume	974.53K	Price	10.97
IPO	Jun 28, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.03% -6.08%	Trades		Volume	702,441	Change	-3.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Wells Fargo	Overweight	$17
Jun-10-25	Resumed	Guggenheim	Buy	$18
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Nov-13-25 04:15PM	Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire)
Nov-04-25 08:00AM	Alumis to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Aug-29-25 07:00AM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-25 04:05PM	Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 05:31PM	TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications \| DelveInsight (PR Newswire)
10:23AM	Loading…
Jul-29-25 10:23AM	Alumis (ALMS) Merges with ACELYRIN (Insider Monkey)
Jul-24-25 07:30AM	Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Jul-14-25 04:05PM	Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary (GlobeNewswire)
May-30-25 05:23AM	Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy (Clinical Trials Arena) -10.49%
May-29-25 04:15PM	Alumis to Present at the Jefferies Global Healthcare Investor Conference (GlobeNewswire)
07:55AM	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
May-21-25 09:10AM	Alumis Completes Merger with ACELYRIN (GlobeNewswire)
May-14-25 04:05PM	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire) +18.63%
May-13-25 01:00PM	Alumis Stockholders Approve Merger with ACELYRIN (GlobeNewswire) -15.05%
01:00PM	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire)
04:30PM	Loading…
May-06-25 04:30PM	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote FOR the Proposed Transaction with Alumis (GlobeNewswire) +10.11%
May-02-25 01:45PM	Acelyrin urges stockholders to vote for proposed merger with Alumis (TipRanks) +19.84%
May-01-25 01:30PM	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis (GlobeNewswire) -7.49%
Apr-29-25 01:22PM	Acelyrin should liquidate instead of merging with Alumis, investor says (BioPharma Dive) +5.10%
Apr-21-25 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire) -6.00%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -15.05%
Apr-07-25 01:43PM	Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High (Seeking Alpha)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) +17.68%
Mar-25-25 10:51AM	Alumis and Kaken sign agreement in Japan to develop ESK-001 (Pharmaceutical Technology) +5.96%
02:30AM	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan (GlobeNewswire)
Mar-21-25 07:08AM	Why Alumis Inc. (ALMS) Went Down On Thursday? (InsiderMonkey) +5.04%
Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire) -18.31%
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	Loading…
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Dec 05 '25	Buy	9.84	186,377	1,833,760	1,265,253	Dec 09 07:13 PM
AKKARAJU SRINIVAS	Director	Dec 03 '25	Buy	7.75	100,000	775,000	1,012,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 02 '25	Buy	7.55	96,000	724,800	912,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 04 '25	Buy	8.18	66,027	540,101	1,078,876	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 01 '25	Buy	7.46	86,350	644,171	816,849	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 26 '25	Buy	7.64	48,537	370,823	691,797	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 28 '25	Buy	7.64	38,702	295,683	730,499	Dec 01 06:09 PM
Foresite Capital Management VI	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Tananbaum James B.	Director	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Foresite Labs, LLC	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:01 PM
AKKARAJU SRINIVAS	Director	Nov 20 '25	Buy	7.20	125,743	905,350	643,260	Nov 24 06:50 PM
Foresite Labs, LLC	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:54 PM
Foresite Capital Management VI	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:52 PM
Tananbaum James B.	Director	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:51 PM
AKKARAJU SRINIVAS	Director	Nov 19 '25	Buy	6.56	137,772	903,784	517,517	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 18 '25	Buy	6.05	102,652	621,045	379,745	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 17 '25	Buy	5.51	914	5,036	277,093	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 13 '25	Buy	5.25	276,179	1,449,940	276,179	Nov 17 04:59 PM
Tananbaum James B.	Director	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:48 PM
Tananbaum James B.	Director	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:48 PM
Foresite Labs, LLC	10% Owner	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:48 PM
Foresite Labs, LLC	10% Owner	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:48 PM
Foresite Capital Management VI	10% Owner	May 02 '25	Buy	4.62	25,000	115,500	4,227,670	May 06 09:47 PM
Foresite Capital Management VI	10% Owner	May 06 '25	Buy	4.34	20,000	86,800	4,247,670	May 06 09:47 PM
AKKARAJU SRINIVAS	Director	May 05 '25	Buy	4.67	160,370	749,676	3,586,788	May 06 06:52 PM
AKKARAJU SRINIVAS	Director	May 02 '25	Buy	4.55	159,920	727,636	3,426,418	May 06 06:52 PM
Colowick Alan	Director	Apr 01 '25	Buy	6.97	16,104	112,309	16,104	Apr 03 06:05 PM
Colowick Alan	Director	Apr 02 '25	Buy	7.49	2,300	17,235	18,404	Apr 03 06:05 PM
Babler Martin	President, CEO and Chairman	Apr 01 '25	Buy	6.44	15,650	100,733	106,454	Apr 03 06:05 PM

Open in Screener

MLYS

Mineralys Therapeutics Inc

Dec 26 • 04:00PM ET

37.14

-0.29 -0.77 %

Healthcare • Biotechnology • USA • NASD

MLYS Mineralys Therapeutics Inc daily Stock Chart

Peers: FENC AKBA EOLS ARDX ESPR PDSB KNSA ACXP CRVS ATHE

| Held by: XBI VTI IWM VXF IBB IWO SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-2.96	Insider Own	28.77%	Shs Outstand	78.97M	Perf Week	0.38%
Market Cap	2.94B	Forward P/E	-	EPS next Y	-2.19	Insider Trans	1.00%	Shs Float	56.37M	Perf Month	-11.99%
Enterprise Value	2.35B	PEG	-	EPS next Q	-0.52	Inst Own	79.50%	Short Float	14.10%	Perf Quarter	-7.13%
Income	-171.36M	P/S	-	EPS this Y	35.17%	Inst Trans	18.05%	Short Ratio	5.20	Perf Half Y	170.90%
Sales	0.00M	P/B	5.09	EPS next Y	7.57%	ROA	-39.48%	Short Interest	7.95M	Perf YTD	201.71%
Book/sh	7.30	P/C	4.95	EPS next 5Y	11.46%	ROE	-42.14%	52W High	47.65 -22.06%	Perf Year	207.96%
Cash/sh	7.50	P/FCF	-	EPS past 3/5Y	-116.58% -170.42%	ROIC	-29.73%	52W Low	8.24 350.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.08% 4.84%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.60%	Oper. Margin	-	ATR (14)	2.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.82	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	25.50	EPS Q/Q	53.74%	SMA20	-1.76%	Beta	0.42	Target Price	50.88
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-7.87%	Rel Volume	0.52	Prev Close	37.43
Employees	51	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	SMA200	50.27%	Avg Volume	1.53M	Price	37.14
IPO	Feb 10, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.16% -	Trades		Volume	800,240	Change	-0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Initiated	Jefferies	Hold	$15
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-12-25 11:00AM	Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup (GlobeNewswire)
Dec-05-25 09:55AM	Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet (Zacks)
Nov-26-25 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:02AM	Loading…
Nov-11-25 12:02AM	Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) +5.87%
Nov-10-25 04:05PM	Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.04%
Nov-07-25 06:10PM	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Nov-05-25 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.66%
Nov-03-25 08:00AM	Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-17-25 09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Sep-30-25 12:34PM	Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups (Insider Monkey)
08:00AM	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension (GlobeNewswire)
Sep-29-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? (Zacks)
06:43PM	Loading…
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-16-25 05:41PM	It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps (Motley Fool)
Sep-09-25 12:00PM	What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? (Zacks) +7.15%
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-05-25 09:00AM	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need (GlobeNewswire) +5.07%
Sep-04-25 04:01PM	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.23%
Sep-03-25 11:13AM	Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak (Insider Monkey)
Sep-02-25 09:33PM	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +86.43%
04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:05PM	Why Mineralys Nearly Doubled On AstraZeneca's Hypertension Results (Investor's Business Daily)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-30-25 10:15AM	AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results (Investor's Business Daily)
Aug-18-25 09:55AM	Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade (Zacks) +5.65%
Aug-13-25 03:12AM	Mineralys Therapeutics Inc (MLYS) Q2 2025 Earnings Call Highlights: Pivotal Trial Success and ... (GuruFocus.com)
Aug-12-25 04:05PM	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Aug-04-25 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 (GlobeNewswire)
Jul-25-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? (Zacks)
Jul-01-25 02:42AM	Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM	Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM	Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM	Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM	Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM	Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-12-25 04:05PM	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
May-05-25 04:05PM	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 (GlobeNewswire) -7.49%
Apr-23-25 05:23PM	Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) (GlobeNewswire)
Mar-29-25 02:30PM	Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) (GlobeNewswire)
Mar-25-25 11:28AM	Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
08:00AM	Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET (GlobeNewswire)
Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)
07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension (GlobeNewswire)
06:30AM	Mineralys shares climb on study data for blood pressure drug (BioPharma Dive)
Mar-07-25 04:01PM	Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET (GlobeNewswire)
Feb-13-25 02:19AM	Q4 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ... (GuruFocus.com)
Feb-12-25 07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.04%
Feb-05-25 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 (GlobeNewswire)
Feb-04-25 08:00AM	Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria (GlobeNewswire)
Jan-09-25 08:29AM	Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials (TipRanks)
Jan-08-25 08:00AM	Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension (GlobeNewswire) -13.71%
Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%
Aug-05-24 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.66%
Jul-12-24 07:01PM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares (GuruFocus.com) +6.71%
07:01PM	Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares (GuruFocus.com)
Jun-21-24 03:11AM	Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire) +6.18%
May-02-24 08:00AM	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 (GlobeNewswire)
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Congleton Jon	Chief Executive Officer	Nov 21 '25	Option Exercise	0.54	24,082	13,004	655,387	Nov 24 05:07 PM
Slingsby Brian Taylor	Director	Nov 20 '25	Sale	43.35	1,000,000	43,350,000	7,903,838	Nov 21 06:07 PM
Catalys Pacific Fund, LP	Affiliate	Nov 20 '25	Proposed Sale	42.12	1,000,000	42,120,000		Nov 20 05:19 PM
Levy Adam Scott	CFO and Secretary	Nov 11 '25	Option Exercise	14.11	105,653	1,490,434	138,920	Nov 13 07:01 PM
Levy Adam Scott	CFO and Secretary	Nov 11 '25	Sale	44.88	119,524	5,363,716	19,396	Nov 13 07:01 PM
Congleton Jon	Chief Executive Officer	Nov 11 '25	Sale	45.44	200,000	9,088,499	631,305	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Option Exercise	10.20	15,000	153,000	15,000	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Sale	45.99	15,000	689,797	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 13 '25	Option Exercise	12.15	12,742	154,868	12,742	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 11 '25	Option Exercise	10.20	15,000	153,000	15,000	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 12 '25	Option Exercise	10.20	6,933	70,717	6,933	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 11 '25	Sale	43.98	15,000	659,706	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 13 '25	Sale	46.50	12,742	592,503	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 12 '25	Sale	46.72	6,933	323,886	0	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Proposed Sale	45.99	15,000	689,796		Nov 13 04:04 PM
Gold Alexander M	Director	Nov 12 '25	Proposed Sale	45.45	34,675	1,576,094		Nov 13 04:03 PM
Levy Adam Scott	Officer	Nov 11 '25	Proposed Sale	44.88	119,524	5,363,716		Nov 12 04:32 PM
Congleton Jon	Officer	Nov 11 '25	Proposed Sale	45.44	200,000	9,088,503		Nov 12 04:28 PM
Levy Adam Scott	CFO and Secretary	Oct 13 '25	Sale	42.01	10,758	451,984	116,865	Oct 15 07:04 PM
Congleton Jon	Chief Executive Officer	Oct 13 '25	Sale	42.67	15,100	644,327	831,305	Oct 15 07:04 PM
Rodman David Malcom	Chief Medical Officer	Oct 15 '25	Sale	43.01	10,369	445,982	71,155	Oct 15 07:04 PM
Rodman David Malcom	Officer	Oct 15 '25	Proposed Sale	43.01	10,369	445,983		Oct 15 04:09 PM
Levy Adam Scott	Officer	Oct 13 '25	Proposed Sale	42.01	10,758	451,983		Oct 14 10:13 AM
Congleton Jon	Officer	Oct 13 '25	Proposed Sale	42.67	15,100	644,326		Oct 14 10:09 AM
Rodman David Malcom	Chief Medical Officer	Sep 15 '25	Sale	36.00	11,367	409,266	81,524	Sep 16 06:54 PM
Rodman David Malcom	Officer	Sep 15 '25	Proposed Sale	36.00	11,367	409,266		Sep 15 04:12 PM
AKKARAJU SRINIVAS	Director	Sep 04 '25	Buy	25.50	588,235	14,999,992	588,235	Sep 08 08:07 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 04 '25	Buy	25.50	1,176,470	29,999,985	5,456,521	Sep 08 05:59 PM
Rodman David Malcom	Chief Medical Officer	Aug 12 '25	Option Exercise	1.08	6,349	6,857	104,256	Aug 14 06:02 PM
Rodman David Malcom	Chief Medical Officer	Aug 13 '25	Sale	12.93	11,365	146,987	92,891	Aug 14 06:02 PM
Rodman David Malcom	Officer	Aug 13 '25	Proposed Sale	12.93	11,365	146,987		Aug 13 05:21 PM
Levy Adam Scott	CFO and Secretary	Jul 30 '25	Sale	14.76	59,925	884,372	132,934	Jul 30 08:12 PM
Levy Adam Scott	CFO and Secretary	Jul 28 '25	Sale	14.04	12,946	181,803	193,666	Jul 30 08:12 PM
Levy Adam Scott	CFO and Secretary	Jul 29 '25	Sale	14.00	807	11,302	192,859	Jul 30 08:12 PM
Levy Adam Scott	Officer	Jul 30 '25	Proposed Sale	14.76	59,925	884,370		Jul 30 05:30 PM
Levy Adam Scott	Officer	Jul 29 '25	Proposed Sale	14.00	807	11,302		Jul 30 09:29 AM
Levy Adam Scott	Officer	Jul 28 '25	Proposed Sale	14.04	12,946	181,804		Jul 28 05:38 PM
Congleton Jon	Chief Executive Officer	Jul 11 '25	Sale	14.51	15,884	230,431	846,405	Jul 15 05:02 PM
Levy Adam Scott	CFO and Secretary	Jul 11 '25	Sale	14.45	10,758	155,454	206,612	Jul 15 05:01 PM
Rodman David Malcom	Chief Medical Officer	Jul 14 '25	Option Exercise	1.08	6,349	6,857	109,273	Jul 15 05:00 PM
Rodman David Malcom	Chief Medical Officer	Jul 14 '25	Sale	14.59	11,366	165,879	97,907	Jul 15 05:00 PM
Rodman David Malcom	Officer	Jul 14 '25	Proposed Sale	14.59	11,366	165,879		Jul 14 04:23 PM
Congleton Jon	Officer	Jul 11 '25	Proposed Sale	14.51	15,884	230,430		Jul 11 04:11 PM
Levy Adam Scott	Officer	Jul 11 '25	Proposed Sale	14.45	10,758	155,454		Jul 11 04:10 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '25	Option Exercise	1.08	6,348	6,856	113,017	Jun 16 04:03 PM
Rodman David Malcom	Chief Medical Officer	Jun 13 '25	Sale	14.60	11,366	165,931	101,651	Jun 16 04:03 PM
Rodman David Malcom	Officer	Jun 13 '25	Proposed Sale	14.60	11,366	165,931		Jun 13 04:23 PM
Rodman David Malcom	Chief Medical Officer	May 14 '25	Sale	15.29	11,366	173,774	106,669	May 15 07:01 PM
Rodman David Malcom	Officer	May 14 '25	Proposed Sale	15.29	11,366	173,774		May 14 04:24 PM
Rodman David Malcom	Chief Medical Officer	May 12 '25	Option Exercise	1.08	6,349	6,857	118,035	May 13 08:57 PM
Slingsby Brian Taylor	Director	Mar 13 '25	Buy	13.50	259,259	3,499,996	8,903,838	Apr 25 07:01 PM
Rodman David Malcom	Chief Medical Officer	Apr 14 '25	Option Exercise	1.08	6,348	6,856	123,052	Apr 15 08:39 PM
Rodman David Malcom	Chief Medical Officer	Apr 14 '25	Sale	14.53	11,366	165,185	111,686	Apr 15 08:39 PM
Levy Adam Scott	CFO and Secretary	Apr 11 '25	Sale	12.06	10,757	129,684	215,340	Apr 15 08:36 PM
Congleton Jon	Chief Executive Officer	Apr 11 '25	Sale	12.19	15,319	186,803	862,289	Apr 15 08:33 PM
Rodman David Malcom	Officer	Apr 14 '25	Proposed Sale	14.53	11,366	165,185		Apr 14 04:11 PM
Levy Adam Scott	Officer	Apr 11 '25	Proposed Sale	12.06	10,757	129,684		Apr 11 04:10 PM
Congleton Jon	Officer	Apr 11 '25	Proposed Sale	12.19	15,319	186,804		Apr 11 04:10 PM
Rodman David Malcom	Chief Medical Officer	Apr 01 '25	Option Exercise	1.08	1,606	1,734	172,475	Apr 03 05:36 PM
Rodman David Malcom	Chief Medical Officer	Apr 01 '25	Sale	15.76	55,771	879,008	116,704	Apr 03 05:36 PM
Rodman David Malcom	Officer	Apr 01 '25	Proposed Sale	15.76	55,771	879,009		Apr 01 04:44 PM
Samsara BioCapital GP, LLC	10% Owner	Mar 13 '25	Buy	13.50	600,000	8,100,000	5,674,916	Mar 17 09:05 PM
AKKARAJU SRINIVAS	Director	Mar 13 '25	Buy	13.50	600,000	8,100,000	5,674,916	Mar 17 09:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 13 '25	Buy	13.50	1,296,296	17,499,996	4,280,051	Mar 17 07:56 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '25	Option Exercise	1.08	6,349	6,857	170,869	Mar 13 05:15 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '25	Option Exercise	1.08	6,348	6,856	164,520	Feb 13 05:29 PM
Levy Adam Scott	CFO and Secretary	Jan 13 '25	Sale	9.10	10,757	97,864	226,097	Jan 15 09:46 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '25	Option Exercise	0.84	11,367	9,567	158,172	Jan 15 09:45 PM
Congleton Jon	Chief Executive Officer	Jan 13 '25	Sale	9.06	18,333	166,082	877,608	Jan 15 09:44 PM
Congleton Jon	Officer	Jan 13 '25	Proposed Sale	9.06	18,333	166,083		Jan 13 06:34 PM
Levy Adam Scott	Officer	Jan 13 '25	Proposed Sale	9.10	10,757	97,864		Jan 13 06:21 PM

SRRK

Scholar Rock Holding Corp

ALMS

Alumis Inc

MLYS

Mineralys Therapeutics Inc

Upgrade your FINVIZ experience